(NASDAQ: EOLS) Evolus's forecast annual revenue growth rate of 16.19% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.39%.
Evolus's revenue in 2026 is $297,176,000.On average, 9 Wall Street analysts forecast EOLS's revenue for 2026 to be $21,900,493,834, with the lowest EOLS revenue forecast at $20,919,389,185, and the highest EOLS revenue forecast at $22,673,406,515. On average, 9 Wall Street analysts forecast EOLS's revenue for 2027 to be $25,759,201,841, with the lowest EOLS revenue forecast at $23,788,534,744, and the highest EOLS revenue forecast at $27,351,870,396.
In 2028, EOLS is forecast to generate $30,473,448,716 in revenue, with the lowest revenue forecast at $27,518,423,970 and the highest revenue forecast at $33,435,630,061.